Search research articles
Contact Us
Filters
Showing results (21-30 of 119) with videos related to
Page
of 12
Sort By:
Rheumatology (Oxford, England)
|
June 23, 2016
Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis
Frank Behrens, Michaela Koehm, Diamant Thaçi, et al.
Arthritis Care & Research
|
October 9, 2012
Leflunomide in psoriatic arthritis: results from a large European prospective observational study
Frank Behrens, Christoph Finkenwirth, Karel Pavelka, et al.
Rheumatology (Oxford, England)
|
October 29, 2014
Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature
Frank Behrens, Juan D Cañete, Ignazio Olivieri, et al.
The Journal of Rheumatology
|
November 17, 2017
Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature
Laure Gossec, Dennis McGonagle, Tatiana Korotaeva, et al.
Therapeutic Advances in Musculoskeletal Disease
|
June 9, 2025
Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab
Jan Brandt-Jürgens, Martin Rudwaleit, Frank Behrens, et al.
Modern Rheumatology
|
August 29, 2020
High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study
Frank Behrens, Jürgen Rech, Diamant Thaçi, et al.
The Journal of Rheumatology
|
April 3, 2018
Simultaneous Response in Several Domains in Patients with Psoriatic Disease Treated with Etanercept as Monotherapy or in Combination with Conventional Synthetic Disease-modifying Antirheumatic Drugs
Frank Behrens, Lothar Meier, Jörg C Prinz, et al.
RMD Open
|
September 21, 2018
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
Peter Nash, Frank Behrens, Ana-Maria Orbai, et al.
Scientific Reports
|
March 22, 2025
Mechanical forces trigger invasive behavior in synovial fibroblasts through N-cadherin/ADAM15 -dependent modulation of LncRNA H19
Tomasz Janczi, Beate Böhm, Yuliya Fehrl, et al.
Medicine
|
May 9, 2020
Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumab
Marc Schmalzing, Frank Behrens, Eva C Schwaneck, et al.
Page
of 12
Search research articles
Search
Showing results (21-30 of 119) with videos related to
Sort By:
Page
of 12
Rheumatology (Oxford, England)
|
June 23, 2016
Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis
Frank Behrens, Michaela Koehm, Diamant Thaçi, et al.
Arthritis Care & Research
|
October 9, 2012
Leflunomide in psoriatic arthritis: results from a large European prospective observational study
Frank Behrens, Christoph Finkenwirth, Karel Pavelka, et al.
Rheumatology (Oxford, England)
|
October 29, 2014
Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature
Frank Behrens, Juan D Cañete, Ignazio Olivieri, et al.
The Journal of Rheumatology
|
November 17, 2017
Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature
Laure Gossec, Dennis McGonagle, Tatiana Korotaeva, et al.
Therapeutic Advances in Musculoskeletal Disease
|
June 9, 2025
Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab
Jan Brandt-Jürgens, Martin Rudwaleit, Frank Behrens, et al.
Modern Rheumatology
|
August 29, 2020
High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study
Frank Behrens, Jürgen Rech, Diamant Thaçi, et al.
The Journal of Rheumatology
|
April 3, 2018
Simultaneous Response in Several Domains in Patients with Psoriatic Disease Treated with Etanercept as Monotherapy or in Combination with Conventional Synthetic Disease-modifying Antirheumatic Drugs
Frank Behrens, Lothar Meier, Jörg C Prinz, et al.
RMD Open
|
September 21, 2018
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
Peter Nash, Frank Behrens, Ana-Maria Orbai, et al.
Scientific Reports
|
March 22, 2025
Mechanical forces trigger invasive behavior in synovial fibroblasts through N-cadherin/ADAM15 -dependent modulation of LncRNA H19
Tomasz Janczi, Beate Böhm, Yuliya Fehrl, et al.
Medicine
|
May 9, 2020
Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumab
Marc Schmalzing, Frank Behrens, Eva C Schwaneck, et al.
Page
of 12